Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (526) 526
humans (443) 443
life sciences & biomedicine (405) 405
animals (253) 253
male (207) 207
cholesterol (192) 192
female (175) 175
proprotein convertase 9 (158) 158
proteins (129) 129
mice (123) 123
multidisciplinary sciences (121) 121
science & technology - other topics (121) 121
lipids (120) 120
lipoproteins (116) 116
cholesterol, ldl - blood (107) 107
low density lipoproteins (107) 107
middle aged (106) 106
kexin (103) 103
subtilisin (103) 103
hypercholesterolemia (96) 96
proprotein convertases - metabolism (95) 95
research (94) 94
cardiovascular system & cardiology (92) 92
abridged index medicus (91) 91
pcsk9 (89) 89
proprotein convertases (88) 88
statins (88) 88
serine endopeptidases - genetics (87) 87
serine endopeptidases - metabolism (87) 87
cardiovascular disease (86) 86
mutation (85) 85
research article (84) 84
analysis (79) 79
proprotein convertases - genetics (79) 79
cardiac & cardiovascular systems (78) 78
antibodies, monoclonal - therapeutic use (77) 77
atherosclerosis (76) 76
biochemistry & molecular biology (76) 76
proprotein convertase 9 - antagonists & inhibitors (75) 75
adult (73) 73
enzymes (73) 73
low density lipoprotein (73) 73
risk factors (73) 73
serine endopeptidases - immunology (72) 72
medicine (71) 71
monoclonal antibodies (71) 71
proprotein convertase 9 - immunology (71) 71
proprotein convertases - immunology (70) 70
biochemistry (69) 69
cell biology (69) 69
science (68) 68
hypercholesterolemia - drug therapy (66) 66
aged (65) 65
endocrinology & metabolism (65) 65
physiological aspects (65) 65
rodents (63) 63
gene expression (62) 62
biological and medical sciences (59) 59
receptors, ldl - metabolism (59) 59
anticholesteremic agents - therapeutic use (57) 57
cardiovascular diseases (56) 56
proprotein convertases - antagonists & inhibitors (55) 55
treatment outcome (55) 55
diabetes (54) 54
immunology (54) 54
pharmacology & pharmacy (52) 52
proprotein convertase 9 - metabolism (52) 52
genetic aspects (51) 51
lipoprotein receptors (49) 49
metabolism (49) 49
receptors, ldl - genetics (49) 49
mice, inbred c57bl (46) 46
amino acid sequence (45) 45
patients (45) 45
proprotein convertase subtilisin/kexin type 9 (45) 45
health aspects (44) 44
studies (44) 44
cell line (43) 43
genetics (43) 43
clinical trials (42) 42
rats (42) 42
antibodies (41) 41
proprotein convertase 9 - genetics (41) 41
genes (40) 40
medical research (40) 40
molecular sequence data (40) 40
antibodies, monoclonal - adverse effects (39) 39
cholesterol - blood (38) 38
inflammation (38) 38
biomarkers - blood (37) 37
biological sciences (36) 36
biology (36) 36
insulin (36) 36
medical sciences (36) 36
mice, knockout (36) 36
proteases (35) 35
signal transduction (35) 35
liver (34) 34
cardiovascular (33) 33
care and treatment (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (571) 571
Japanese (4) 4
Spanish (4) 4
Chinese (2) 2
German (2) 2
Italian (2) 2
French (1) 1
Norwegian (1) 1
Portuguese (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis
by Navarese, Eliano Pio and Kołodziejczak, Michalina and Schulze, Volker and Gurbel, Paul A and Tantry, Udaya and Lin, Yingfeng and Brockmeyer, Maximilian and Kandzari, David E and Kubica, Julia M and D'Agostino, Ralph B and Kubica, Jacek and Volpe, Massimo and Agewall, Stefan and Kereiakes, Dean J and Kelm, Malte
Annals of internal medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 40 - 51
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypercholesterolemia - blood | Creatine Kinase - blood | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Cause of Death | Proprotein Convertases - immunology | Anticholesteremic Agents - therapeutic use | Serine Endopeptidases - immunology | Angina, Unstable - prevention & control | Cardiovascular Diseases - mortality | Female | Myocardial Infarction - prevention & control | Lipoprotein(a) - blood | Proprotein Convertase 9 | Monoclonal antibodies | Complications and side effects | Dosage and administration | Hypercholesterolemia | Research | Drug therapy | Proteins | Patient safety | Lipids | Adults | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
by Koren, Michael J, Dr and Scott, Rob, MD and Kim, Jae B, MD and Knusel, Beat, PhD and Liu, Thomas, PhD and Lei, Lei, PhD and Bolognese, Michael, MD and Wasserman, Scott M, MD
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 1995 - 2006
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Metabolic diseases | General aspects | Medical sciences | Disorders of blood lipids. Hyperlipoproteinemia | Proprotein Convertases - antagonists & inhibitors | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Hypercholesterolemia - drug therapy | Proprotein Convertases - immunology | Young Adult | Anticholesteremic Agents - therapeutic use | Immunoglobulin G - immunology | Adolescent | Serine Endopeptidases - immunology | Aged, 80 and over | Adult | Female | Aged | Proprotein Convertase 9 | Monoclonal antibodies | Usage | Hypercholesterolemia | Research | Drug therapy | Heart | Thyroid diseases | Clinical trials | Cardiovascular disease | Mutation | Apolipoproteins | Cholesterol | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
by Giugliano, Robert P, Dr and Desai, Nihar R, MD and Kohli, Payal, MD and Rogers, William J, Prof and Somaratne, Ransi, MD and Huang, Fannie, MS and Liu, Thomas, PhD and Mohanavelu, Satishkumar, MS and Hoffman, Elaine B, PhD and McDonald, Shannon T, BSN and Abrahamsen, Timothy E, BA and Wasserman, Scott M, MD and Scott, Robert, MD and Sabatine, Marc S, MD and for the LAPLACE-TIMI 57 Investigators and LAPLACE-TIMI 57 Investigators
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9858, pp. 2007 - 2017
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | Metabolic diseases | General aspects | Medical sciences | Disorders of blood lipids. Hyperlipoproteinemia | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Ezetimibe | Male | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Young Adult | Immunoglobulin G - immunology | Serine Endopeptidases - immunology | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Drug Therapy, Combination | Double-Blind Method | Azetidines - adverse effects | Treatment Outcome | Anticholesteremic Agents - adverse effects | Proprotein Convertases - immunology | Azetidines - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Analysis of Variance | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Cholesterol, HDL - blood | Aged | Proprotein Convertase 9 | Monoclonal antibodies | Usage | Hypercholesterolemia | Research | Drug therapy | Clinical trials | Cardiovascular disease | Apolipoproteins | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE3Leiden.CETP mice
by Landlinger, Christine and Pouwer, Marianne G and Juno, Claudia and van der Hoorn, Jose W. A and Pieterman, Elsbet J and Jukema, J. Wouter and Staffler, Guenther and Princen, Hans M. G and Galabova, Gergana
European heart journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2499 - U143
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Biomarkers - metabolism | Hypercholesterolemia - immunology | Antibodies - metabolism | Cholesterol, HDL - metabolism | NLR Family, Pyrin Domain-Containing 3 Protein - metabolism | Plaque, Atherosclerotic - prevention & control | Mice, Transgenic | Vaccines, Subunit - immunology | Vasculitis - prevention & control | Proprotein Convertase 9 - immunology | Vasculitis - immunology | Coronary Disease - prevention & control | Intercellular Adhesion Molecule-1 - metabolism | Animals | NLR Family, Pyrin Domain-Containing 3 Protein - immunology | Proprotein Convertase 9 - antagonists & inhibitors | Vaccines, Subunit - administration & dosage | Apolipoprotein E3 - deficiency | Aortic Diseases - prevention & control | Female | Hypercholesterolemia - prevention & control | Atherosclerosis - prevention & control | Disease Models, Animal | Index Medicus | Basic Science | Systemic and vascular inflammation | APOE3Leiden.CETP mice | Editor's Choice | Atherosclerosis | Anti-PCSK9 vaccine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome a narrative review
by Navarese, Eliano P and Kołodziejczak, Michalina and Kereiakes, Dean J and Tantry, Udaya S and O'connor, Christopher and Gurbel, Paul A
Annals of internal medicine, ISSN 0003-4819, 05/2016, Volume 164, Issue 9, pp. 600 - 607
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Proprotein Convertase 9 - immunology | Acute Coronary Syndrome - blood | Immunologic Factors - pharmacokinetics | Acute Coronary Syndrome - complications | Plaque, Atherosclerotic - therapy | Proprotein Convertase 9 - antagonists & inhibitors | Time Factors | Fibrinolytic Agents - therapeutic use | Proprotein Convertase 9 - blood | Anti-Inflammatory Agents - therapeutic use | Acute Coronary Syndrome - therapy | Immunologic Factors - pharmacology | Lipoproteins, LDL - blood | Immunologic Factors - therapeutic use | Enzyme inhibitors | Atherosclerotic plaque | Development and progression | Genetic aspects | Lipid metabolism | Acute coronary syndrome | Health aspects | Monoclonal antibodies | Coronary heart disease | Cardiac patients | Medical research | Cardiovascular disease | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9　― Lessons From Recent Clinical Trials
by Ishii, Hideki and Murohara, Toyoaki
Circulation journal : official journal of the Japanese Circulation Society, ISSN 1346-9843, 2017, Volume 81, Issue 10, pp. 1386 - 1387
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Subtilisins | Humans | Serine Endopeptidases - immunology | Cholesterol, LDL | Lipids | Antibodies, Monoclonal | Proprotein Convertases - immunology | Proprotein Convertase 9 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Discordant response of low density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
by Edmiston, Jonathan B and Brooks, Nathan and Tavori, Hagai and Minnier, Jessica and Duell, Bart and Purnell, Jonathan Q and Kaufman, Tina and Wojcik, Cezary and Voros, Szilard and Fazio, Sergio and Shapiro, Michael D
Journal of clinical lipidology, ISSN 1933-2874, 2017, Volume 11, Issue 3, pp. 667 - 673
Cardiovascular | Low-density lipoprotein | Proprotein convertase subtilisin/kexin type 9 | Lipoprotein(a) | Cholesterol | Discordance | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Humans | Middle Aged | Cholesterol, LDL - blood | Female | Male | Lipoprotein(a) - blood | Proprotein Convertase 9 - immunology | Antibodies, Monoclonal - immunology | Cohort Studies | Monoclonal antibodies | Cholesterol, LDL | Research | Lipoprotein A | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
by Seidah, Nabil G and Prat, Annik and Pirillo, Angela and Catapano, Alberico Luigi and Norata, Giuseppe Danilo
Cardiovascular research, ISSN 0008-6363, 03/2019, Volume 115, Issue 3, pp. 510 - 518
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hypercholesterolemia - immunology | Cholesterol - blood | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Vaccines - therapeutic use | Proprotein Convertase 9 - immunology | Serine Proteinase Inhibitors - therapeutic use | Hypercholesterolemia - enzymology | Serine Proteinase Inhibitors - adverse effects | Hypercholesterolemia - therapy | Gene Targeting | Receptors, LDL - antagonists & inhibitors | Gene Silencing | Receptors, LDL - metabolism | Treatment Outcome | Proprotein Convertase 9 - genetics | Biomarkers - blood | Proprotein Convertase 9 - metabolism | Anticholesteremic Agents - adverse effects | Vaccines - adverse effects | Animals | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Hypercholesterolemia - genetics | Genetic Therapy - adverse effects | Genetic Therapy - methods | Index Medicus | Monoclonal antibodies | Gene silencing | PCSK9 | Reviews | LDL-C | Editor's Choice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
by Ason, Brandon and Van Der Hoorn, José W. A and Chan, Joyce and Lee, Edward and Pieterman, Elsbet J and Nguyen, Kathy Khanh and Di, Mei and Shetterly, Susan and Tang, Jie and Yeh, Wen-Chen and Schwarz, Margrit and Jukema, J. Wouter and Scott, Rob and Wasserman, Scott M and Princen, Hans M. G and Jackson, Simon
Journal of lipid research, ISSN 0022-2275, 11/2014, Volume 55, Issue 11, pp. 2370 - 2379
Anti-proprotein convertase subtilisin/kexin type 9 antibody | Proprotein convertase subtilisin/kexin type 9 | Low density lipoprotein receptor | Apolipoprotein E | Life Sciences & Biomedicine | Biochemistry & Molecular Biology | Science & Technology | Apolipoproteins E - deficiency | Atherosclerosis - genetics | Cholesterol - blood | Humans | Proprotein Convertases - genetics | Atherosclerosis - enzymology | Liver - drug effects | Serine Endopeptidases - genetics | Serine Endopeptidases - immunology | Antibodies - immunology | Female | Serine Endopeptidases - deficiency | Liver - metabolism | Proprotein Convertases - metabolism | Receptors, LDL - metabolism | Gene Knockout Techniques | Proprotein Convertases - deficiency | Atherosclerosis - metabolism | Proprotein Convertases - immunology | Atherosclerosis - blood | Animals | Mice | Serine Endopeptidases - metabolism | Cholesterol Ester Transfer Proteins - metabolism | Proprotein Convertase 9 | Index Medicus | kexin type 9 antibody | apolipoprotein E | kexin type 9 | low density lipoprotein receptor | proprotein convertase subtilisin | anti-proprotein convertase subtilisin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights